Literature DB >> 17981592

Bone tissue engineering and repair by gene therapy.

Volker M Betz1, Oliver B Betz, Mitchel B Harris, Mark S Vrahas, Christopher H Evans.   

Abstract

Many clinical conditions require the stimulation of bone growth. The use of recombinant bone morphogenetic proteins does not provide a satisfying solution to these conditions due to delivery problems and high cost. Gene therapy has emerged as a very promising approach for bone repair that overcomes limitations of protein-based therapy. Several preclinical studies have shown that gene transfer technology has the ability to deliver osteogenic molecules to precise anatomical locations at therapeutic levels for sustained periods of time. Both in-vivo and ex-vivo transduction of cells can induce bone formation at ectopic and orthotopic sites. Genetic engineering of adult stem cells from various sources with osteogenic genes has led to enhanced fracture repair, spinal fusion and rapid healing of bone defects in animal models. This review describes current viral and non-viral gene therapy strategies for bone tissue engineering and repair including recent work from the author's laboratory. In addition, the article discusses the potential of gene-enhanced tissue engineering to enter widespread clinical use.

Entities:  

Mesh:

Year:  2008        PMID: 17981592     DOI: 10.2741/2724

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  25 in total

Review 1.  Clinical translation of controlled protein delivery systems for tissue engineering.

Authors:  Kara L Spiller; Gordana Vunjak-Novakovic
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

2.  BMP-2 gene modified canine bMSCs promote ectopic bone formation mediated by a nonviral PEI derivative.

Authors:  Kaige Lü; Deliang Zeng; Yilin Zhang; Lunguo Xia; Ling Xu; David L Kaplan; Xinquan Jiang; Fuqiang Zhang
Journal:  Ann Biomed Eng       Date:  2011-02-23       Impact factor: 3.934

3.  Functionalization of scaffolds with chimeric anti-BMP-2 monoclonal antibodies for osseous regeneration.

Authors:  Sahar Ansari; Alireza Moshaverinia; Sung Hee Pi; Alexander Han; Alaa I Abdelhamid; Homayoun H Zadeh
Journal:  Biomaterials       Date:  2013-09-19       Impact factor: 12.479

Review 4.  Gene therapy: implications for craniofacial regeneration.

Authors:  Erica L Scheller; Luis G Villa-Diaz; Paul H Krebsbach
Journal:  J Craniofac Surg       Date:  2012-01       Impact factor: 1.046

5.  Biomechanical analysis of engineered bone with anti-BMP2 antibody immobilized on different scaffolds.

Authors:  Sahar Ansari; Jin-Ho Phark; Sillas Duarte; Maike Paulino da Silva; Navid Sharifzadeh; Alireza Moshaverinia; Homayoun H Zadeh
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2015-08-07       Impact factor: 3.368

6.  Cyclic arginine-glycine-aspartate peptides enhance three-dimensional stem cell osteogenic differentiation.

Authors:  Susan X Hsiong; Tanyarut Boontheekul; Nathaniel Huebsch; David J Mooney
Journal:  Tissue Eng Part A       Date:  2009-02       Impact factor: 3.845

7.  Co-encapsulation of anti-BMP2 monoclonal antibody and mesenchymal stem cells in alginate microspheres for bone tissue engineering.

Authors:  Alireza Moshaverinia; Sahar Ansari; Chider Chen; Xingtian Xu; Kentaro Akiyama; Malcolm L Snead; Homayoun H Zadeh; Songtao Shi
Journal:  Biomaterials       Date:  2013-06-14       Impact factor: 12.479

Review 8.  Gene therapy: design and prospects for craniofacial regeneration.

Authors:  E L Scheller; P H Krebsbach
Journal:  J Dent Res       Date:  2009-07       Impact factor: 6.116

9.  Osteogenic differentiation of mesenchymal stem cells promoted by overexpression of connective tissue growth factor.

Authors:  Jin-jing Wang; Feng Ye; Li-jia Cheng; Yu-jun Shi; Ji Bao; Huai-qiang Sun; Wei Wang; Peng Zhang; Hong Bu
Journal:  J Zhejiang Univ Sci B       Date:  2009-05       Impact factor: 3.066

10.  Gene delivery to human adult and embryonic cell-derived stem cells using biodegradable nanoparticulate polymeric vectors.

Authors:  F Yang; J J Green; T Dinio; L Keung; S-W Cho; H Park; R Langer; D G Anderson
Journal:  Gene Ther       Date:  2009-01-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.